Skip to content

PUMA BIOTECHNOLOGY, INC.

PBYI · XNAS

CIK 1401667fmd_0E1RV1AJ54E24SWWCTQXZANRZGManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2008 to Sep 30, 2026, 68 periods

Latest annual · FY2025

Millions
Total revenues
228
Gross profit
170
Operating income
37
Net income
31
Free cash flow
42

Latest quarter · Q3 FY2026

Millions
Total revenues
55
Gross profit
40
Operating income
5
Net income
6
Free cash flow
15

Daily close · PBYIIEX trades only

Nov 13, 2025 to Nov 11, 2026 · 250 sessions

8.09 USD

4681012Nov 13, 2025May 14, 2026Nov 11, 2026Vol

Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms

Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
0.0%
Revenue, 5 yearsFY2020 to FY2025
+0.3%
Net income, 5 yearsFY2020 to FY2025
n/m

PUMA BIOTECHNOLOGY, INC. (PBYI) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$228.4 million$230.5 million-0.9%10-K 2026-02-26 · proof
Gross profit$170.2 million$166.1 million+2.5%10-K 2026-02-26 · proof
Operating income$37.3 million$31 million+20.5%10-K 2026-02-26 · proof
Net income$31.1 million$30.3 million+2.8%10-K 2026-02-26 · proof
Cash from operating activities$41.8 million$38.9 million+7.4%10-K 2026-02-26 · proof
Free cash flow$41.7 million$38.9 million+7.4%10-K 2026-02-26 · proof
Total assets$216.3 million$213.3 million+1.4%10-K 2026-02-26 · proof
Total liabilities$86 million$121.2 million-29.1%10-K 2026-02-26 · proof
Cash and cash equivalents$29.6 million$69.2 million-57.2%10-K 2026-02-26 · proof
Total debt$22.5 million$67 million-66.4%10-K 2026-02-26 · proof
What was PUMA BIOTECHNOLOGY, INC. (PBYI)'s revenue in fiscal 2025?
PUMA BIOTECHNOLOGY, INC. (PBYI) reported revenue of $228.4 million for fiscal 2025 (the year ended Dec 31, 2025), against $230.5 million the year before (-0.9%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
What was PUMA BIOTECHNOLOGY, INC. (PBYI)'s gross profit in fiscal 2025?
PUMA BIOTECHNOLOGY, INC. (PBYI) reported gross profit of $170.2 million for fiscal 2025 (the year ended Dec 31, 2025), against $166.1 million the year before (+2.5%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
What was PUMA BIOTECHNOLOGY, INC. (PBYI)'s operating income in fiscal 2025?
PUMA BIOTECHNOLOGY, INC. (PBYI) reported operating income of $37.3 million for fiscal 2025 (the year ended Dec 31, 2025), against $31 million the year before (+20.5%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
What was PUMA BIOTECHNOLOGY, INC. (PBYI)'s net income in fiscal 2025?
PUMA BIOTECHNOLOGY, INC. (PBYI) reported net income of $31.1 million for fiscal 2025 (the year ended Dec 31, 2025), against $30.3 million the year before (+2.8%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
What was PUMA BIOTECHNOLOGY, INC. (PBYI)'s cash from operating activities in fiscal 2025?
PUMA BIOTECHNOLOGY, INC. (PBYI) reported cash from operating activities of $41.8 million for fiscal 2025 (the year ended Dec 31, 2025), against $38.9 million the year before (+7.4%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
What was PUMA BIOTECHNOLOGY, INC. (PBYI)'s free cash flow in fiscal 2025?
PUMA BIOTECHNOLOGY, INC. (PBYI) reported free cash flow of $41.7 million for fiscal 2025 (the year ended Dec 31, 2025), against $38.9 million the year before (+7.4%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
What are PUMA BIOTECHNOLOGY, INC. (PBYI)'s total assets?
As of Dec 31, 2025, PUMA BIOTECHNOLOGY, INC. (PBYI) reported total assets of $216.3 million, against $213.3 million a year earlier (+1.4%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
What are PUMA BIOTECHNOLOGY, INC. (PBYI)'s total liabilities?
As of Dec 31, 2025, PUMA BIOTECHNOLOGY, INC. (PBYI) reported total liabilities of $86 million, against $121.2 million a year earlier (-29.1%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
What are PUMA BIOTECHNOLOGY, INC. (PBYI)'s cash and cash equivalents?
As of Dec 31, 2025, PUMA BIOTECHNOLOGY, INC. (PBYI) reported cash and cash equivalents of $29.6 million, against $69.2 million a year earlier (-57.2%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC
What is PUMA BIOTECHNOLOGY, INC. (PBYI)'s total debt?
As of Dec 31, 2025, PUMA BIOTECHNOLOGY, INC. (PBYI) reported total debt of $22.5 million, against $67 million a year earlier (-66.4%). Source: the 10-K filed with the SEC on Feb 26, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:PBYI&period_type=annual&limit=5"

Information only, not investment advice.